Chinese biotech start-ups are going up against Western drug makers - and they could win A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a ...

A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.

Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests certain approved drugs could possibly be repurposed for a severe fatigue condition that currently ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

Learn more about whether Alvotech or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.